165 related articles for article (PubMed ID: 27058752)
1. Oncogenic KRAS signaling and YAP1/β-catenin: Similar cell cycle control in tumor initiation.
Nussinov R; Tsai CJ; Jang H; Korcsmáros T; Csermely P
Semin Cell Dev Biol; 2016 Oct; 58():79-85. PubMed ID: 27058752
[TBL] [Abstract][Full Text] [Related]
2. Alternative splicing reverses the cell-intrinsic and cell-extrinsic pro-oncogenic potentials of YAP1.
Ben C; Wu X; Takahashi-Kanemitsu A; Knight CT; Hayashi T; Hatakeyama M
J Biol Chem; 2020 Oct; 295(41):13965-13980. PubMed ID: 32763976
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
[TBL] [Abstract][Full Text] [Related]
4. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
5. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation.
Nout RA; Bosse T; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; van Eijk R; Ter Haar NT; Smit VT
Gynecol Oncol; 2012 Sep; 126(3):466-73. PubMed ID: 22609107
[TBL] [Abstract][Full Text] [Related]
6. KRAS and YAP1 converge to regulate EMT and tumor survival.
Shao DD; Xue W; Krall EB; Bhutkar A; Piccioni F; Wang X; Schinzel AC; Sood S; Rosenbluh J; Kim JW; Zwang Y; Roberts TM; Root DE; Jacks T; Hahn WC
Cell; 2014 Jul; 158(1):171-84. PubMed ID: 24954536
[TBL] [Abstract][Full Text] [Related]
7. Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.
McCubrey JA; Rakus D; Gizak A; Steelman LS; Abrams SL; Lertpiriyapong K; Fitzgerald TL; Yang LV; Montalto G; Cervello M; Libra M; Nicoletti F; Scalisi A; Torino F; Fenga C; Neri LM; Marmiroli S; Cocco L; Martelli AM
Biochim Biophys Acta; 2016 Dec; 1863(12):2942-2976. PubMed ID: 27612668
[TBL] [Abstract][Full Text] [Related]
8. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
[TBL] [Abstract][Full Text] [Related]
9. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
10. Astaxanthin inhibits NF-κB and Wnt/β-catenin signaling pathways via inactivation of Erk/MAPK and PI3K/Akt to induce intrinsic apoptosis in a hamster model of oral cancer.
Kavitha K; Kowshik J; Kishore TK; Baba AB; Nagini S
Biochim Biophys Acta; 2013 Oct; 1830(10):4433-44. PubMed ID: 23726989
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of β-catenin-mediated transcription.
Han L; Yang Y; Yue X; Huang K; Liu X; Pu P; Jiang H; Yan W; Jiang T; Kang C
Brain Res; 2010 Dec; 1366():9-17. PubMed ID: 20888802
[TBL] [Abstract][Full Text] [Related]
12. Cell adhesion. Mechanical strain induces E-cadherin-dependent Yap1 and β-catenin activation to drive cell cycle entry.
Benham-Pyle BW; Pruitt BL; Nelson WJ
Science; 2015 May; 348(6238):1024-7. PubMed ID: 26023140
[TBL] [Abstract][Full Text] [Related]
13. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
14. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis.
Rosenbluh J; Nijhawan D; Cox AG; Li X; Neal JT; Schafer EJ; Zack TI; Wang X; Tsherniak A; Schinzel AC; Shao DD; Schumacher SE; Weir BA; Vazquez F; Cowley GS; Root DE; Mesirov JP; Beroukhim R; Kuo CJ; Goessling W; Hahn WC
Cell; 2012 Dec; 151(7):1457-73. PubMed ID: 23245941
[TBL] [Abstract][Full Text] [Related]
15. Dual-specificity phosphatases are targets of the Wnt/β-catenin pathway and candidate mediators of β-catenin/Ras signaling interactions.
Zeller E; Mock K; Horn M; Colnot S; Schwarz M; Braeuning A
Biol Chem; 2012 Oct; 393(10):1183-91. PubMed ID: 23089536
[TBL] [Abstract][Full Text] [Related]
16. Cancer cells acquire a drug resistant, highly tumorigenic, cancer stem-like phenotype through modulation of the PI3K/Akt/β-catenin/CBP pathway.
He K; Xu T; Xu Y; Ring A; Kahn M; Goldkorn A
Int J Cancer; 2014 Jan; 134(1):43-54. PubMed ID: 23784558
[TBL] [Abstract][Full Text] [Related]
17. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
[TBL] [Abstract][Full Text] [Related]
18. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
Dogan Turacli I; Ozkan AC; Ekmekci A
Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of RAS/β-catenin interactions.
Zeller E; Hammer K; Kirschnick M; Braeuning A
Arch Toxicol; 2013 Apr; 87(4):611-32. PubMed ID: 23483189
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
